Kamada Ltd's 2025 earnings call reveals strong financial performance with a 12% revenue increase and an optimistic outlook for future growth. Read more.

Kamada Ltd has recently concluded its earnings call for the fourth quarter and full year ended December 31, 2025. The call highlighted the company's solid financial performance, strategic initiatives, and an optimistic outlook for the future. With total revenues reaching $180.5 million, a 12% increase year-over-year, and adjusted EBITDA rising 23% to $42 million, Kamada demonstrates robust growth and operational strength.

Financial Performance

Kamada's financial results for 2025 showcase remarkable growth across various metrics:

• Total Revenues: $180.5 million, up from $161 million in 2024, reflecting a 12% year-over-year increase.
• Adjusted EBITDA: $42 million, a 23% increase compared to $34.1 million in 2024.
• Net Income: $20.2 million or $0.35 per diluted share, marking a 40% increase from $14.5 million or $0.25 per diluted share in the prior year.
• Gross Profit: $76.4 million, with a gross margin of 42% in 2025, slightly down from 43% in 2024 due to product mix dynamics.
• Cash Position: As of December 31, 2025, the company reported cash and cash equivalents of $75.5 million, down from $78.4 million in 2024, but generated $25.5 million from operating activities.

These results align with Kamada's 2025 annual guidance and emphasize its ability to achieve profitable growth through a diverse product portfolio.

Strategic Initiatives

Kamada has focused on several strategic initiatives that have contributed to its success:

• Product Portfolio Expansion: The company continues to invest in the commercialization of its six FDA-approved specialty plasma-derived products, which are crucial for sustaining organic growth in both the U.S. and international markets.
• Biosimilar Market Penetration: Kamada has launched two biosimilar products in Israel with plans for additional launches in 2026. This segment is expected to generate $15 million to $20 million annually within the next four to five years.
• Plasma Collection Centers: The company is ramping up plasma collection at its facilities in Houston and San Antonio, anticipating FDA approval for the latter in the first half of 2026. These centers are expected to generate $8 million to $10 million in annual revenues at full capacity.
• Collaboration and M&A: Kamada is actively pursuing mergers and acquisitions to enhance its product offering and achieve synergies with existing commercial operations. The management emphasized its confidence in executing such transactions in 2026.

“The dividend payment reinforces our confidence in our business prospects,” stated Amir London, CEO of Kamada. “We believe that we have sufficient funds and liquidity to continue investing in commercial growth as well as M&A transactions.”

Future Outlook

Looking ahead, Kamada has set ambitious targets for 2026, indicating continued growth:

• Revenue Guidance: The company anticipates revenues between $200 million and $205 million, reflecting a 13% increase from the 2025 results.
• Adjusted EBITDA Expectations: Projected to be between $50 million and $53 million, representing a growth of 23% year-over-year.
• Organic Growth Strategy: The guidance is based solely on organic growth, highlighting Kamada's commitment to leveraging its existing portfolio.
• Product Growth: The company expects an increase in sales of its lead product, Kedrab, which saw revenues of approximately $54 million in 2025. Additionally, it plans to enhance sales of Cytogam through an ongoing clinical program that aims to demonstrate the product's efficacy in the management of CMV disease.

Management expressed optimism about the growth prospects stemming from their comprehensive strategy, which includes enhancing operational efficiencies and expanding into new markets.

Conclusion

In summary, Kamada Ltd's earnings call underscores a successful year marked by substantial revenue growth, strategic investments, and a forward-looking approach to business development. With plans to expand its product offerings and distribution capabilities, the company is well-positioned for a promising 2026. The commitment to delivering shareholder value through dividends, alongside a proactive growth strategy, reinforces Kamada's potential as a competitive player in the biopharmaceutical industry. Investors can look forward to a year of continued growth and innovation as the company executes its strategic vision.